The estimated Net Worth of Glen C Mac Donald is at least $808 Thousand dollars as of 2 March 2023. Dr Donald owns over 286,292 units of Sesen Bio stock worth over $272,668 and over the last 5 years he sold SESN stock worth over $15,297. In addition, he makes $519,698 as Chief Technology Officer at Sesen Bio.
Sign up
Dr MacDonald SESN stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 286,292 units of SESN stock worth $168,912 on 2 March 2023.
The largest trade he's ever made was exercising 286,292 units of Sesen Bio stock on 2 March 2023 worth over $168,912. On average, Dr trades about 52,037 units every 2 days since 2019. As of 2 March 2023 he still owns at least 432,806 units of Sesen Bio stock.
You can see the complete history of Dr Donald stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Glen C. MacDonald biography
Dr. Glen C. MacDonald is the Chief Technology Officer at Sesen Bio.
What is the salary of Dr MacDonald?
As the Chief Technology Officer of Sesen Bio, the total compensation of Dr MacDonald at Sesen Bio is $519,698. There are 5 executives at Sesen Bio getting paid more, with Thomas Cannell having the highest compensation of $1,404,240.
How old is Dr MacDonald?
Dr MacDonald is 70, he's been the Chief Technology Officer of Sesen Bio since . There are no older and 16 younger executives at Sesen Bio.
What's Dr MacDonald's mailing address?
Glen's mailing address filed with the SEC is C/O SESEN BIO, INC., SUITE 1800, CAMBRIDGE, MA, 02142.
Insiders trading at Sesen Bio
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes, and Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
What does Sesen Bio do?
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
What does Sesen Bio's logo look like?
Complete history of Dr Donald stock trades at Sesen Bio
Sesen Bio executives and stock owners
Sesen Bio executives and other stock owners filed with the SEC include:
-
Thomas Cannell,
President, Chief Executive Officer, Director -
Mark Sullivan,
General Counsel, Corporate Secretary -
Dr. Thomas R. Cannell,
Pres, CEO & Director -
Monica Forbes,
Chief Financial Officer, Treasurer -
Monica Forbes,
CFO & Treasurer -
Dr. Glen C. MacDonald,
Chief Technology Officer -
Jason Keyes,
Independent Director -
Carrie Bourdow,
Independent Director -
Jane Henderson,
Independent Director -
Jay Duker,
Independent Chairman of the Board -
Glen MacDonald,
Chief Technology Officer -
Daniel Lynch,
Independent Director -
John Knighton,
VP & Chief Compliance Officer -
Dr. Gregory L. Verdine Ph.D.,
Co-Founder -
Dr. David Brooks,
Sr. VP of Clinical Devel. -
Julie Hoff,
VP of HR -
Steve Barbera,
VP of Market Access -
Mark R. Sullivan,
Gen. Counsel & Corp. Sec. -
Erin Clark,
VP of Corp. Strategy & Investor Relations -
Elly Ryu,
Corp. Controller & Principal Accounting Officer -
Dr. Gregory L. Verdine,
Co-Founder -
Minori Rosales,
Chief Development Officer -
Leslie Dan,
Director -
Paul G Chaney,
Director -
Abbie Celniker,
Director -
Stephen A Hurly,
President and CEO -
Wendy L Dixon,
Director -
Dennis Kim,
Chief Medical Officer -
Richard F Fitzgerald,
Chief Financial Officer -
Peter Honig,
Director -
Michael A. S. Jewett,
Director -
Kirstin Anderson,
Principal Accounting Officer -
Elly Ryu,
Principal Accounting Officer